The delay drug, given after diagnosis: what the new US teplizumab approval means
The US has approved teplizumab for children just diagnosed with type 1, to protect the insulin they still make. In the UK it is licensed only before diagnosis.
The US has approved teplizumab for children just diagnosed with type 1, to slow the loss of the insulin their body still makes. That is a different group from the one the UK licence covers, so nothing changes about what is available here.
- It covers children aged 8 to 17 diagnosed in the previous six weeks, and it is a US approval only.
- It is not a cure, and nobody comes off insulin: everyone in the trial stayed on it.
- What the trial measured is C-peptide, a by-product released alongside your own insulin, so it shows how much you still make.
- The trial found no significant difference in HbA1c (average glucose over about three months), insulin needed, or serious hypos.
- In the UK it is licensed only for stage 2, the stage before insulin is needed, so there is nothing to request.
An approval for the weeks straight after diagnosis
The US Food and Drug Administration has given accelerated approval to Tzield, the brand name for teplizumab, for children aged 8 to 17 who were diagnosed with stage 3 type 1 diabetes in the previous six weeks. Stage 3 is what most people mean by diagnosis: symptoms, high glucose, insulin started. Every approved use of this drug before now was aimed at the stage before that one.
The evidence behind it is a trial called PROTECT. It enrolled 328 children and teenagers, split two to one between teplizumab and a placebo (a dummy infusion), and gave two courses of 12 daily infusions about six months apart, all in hospital. At 78 weeks the treated group had lost less of their own insulin production, a difference in C-peptide of 0.13 pmol/mL. Of that group, 94.9% still had a peak C-peptide of at least 0.2 pmol/mL, the level counted as clinically meaningful, against 79.2% of those on placebo.
What the trial measured, and what it did not
Accelerated approval is a conditional route. The regulator cleared this use on a laboratory marker judged reasonably likely to predict a benefit, rather than on proof of the benefit itself, and continued approval may depend on confirming that benefit in a further study. That study, a phase 3 trial called BETA-PRESERVE, is still recruiting.
Why that caveat matters is visible in PROTECT itself. The treated children kept more of their own insulin production, but the trial’s other main measures, the insulin they needed, their HbA1c, their time in range (the share of the day spent in the target glucose band) and hypos serious enough to be classed as clinically important, did not differ significantly between the two groups. What has been shown is that the immune attack can be slowed. What has not been shown yet is that slowing it makes daily life with type 1 measurably different.
It also only makes sense while there is something left to protect, which is why the trial recruited people within six weeks of diagnosis rather than months or years later.
Here it is still a drug for the stage before insulin
The MHRA licensed teplizumab in August 2025 for people aged 8 and over with stage 2 type 1: immune markers present and glucose starting to drift, but no symptoms and no insulin needed. We have covered what that UK approval means, how the European decision lined up with it and the first real-world signals separately. The US decision changes none of that.
Several separate things would have to happen for this newer use to reach a child here. The company would need to apply to the MHRA to widen the licence, the MHRA would need to agree, NICE would then judge whether the NHS should pay for it, and services would have to be able to start a course of daily hospital infusions, repeated six months later, inside the first six weeks after a diagnosis. When the EU approved teplizumab for stage 2 in January 2026, Sanofi said it had decided not to progress a second European application for the recently diagnosed use at that time, with next steps under evaluation. There is no UK licence for this use, so there is nothing here to ask for yet.
How much insulin you still make is not the same for everyone
Most people still make some of their own insulin at diagnosis, and for a while afterwards. That stretch is often called the honeymoon period, and it is genuinely unpredictable: some people get months where their insulin needs stay low, others barely notice one. It is not something anyone can influence by trying harder, and when it fades, that is not a sign anything has gone wrong.